Clinical Trials

Enrolling Trials

61-70  of  152
CORRECT- MRD II: Second COloRectal cancer clinical validation study to predict REcurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease
Onitilo, Adedayo A
Stomach, Intestine, Gut - Rectum
Adult
C-14 is a prospective multicenter study that will enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer (CRC), who have sufficient residual formalin-fixed paraffin-embedded (FFPE) tissue available from the primary resection for research testing and are willing to provide FFPE and serial whole blood samples for circulating tumor DNA(ctDNA) analysis.
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Fagbemi, Seth O
Plasma Cell, Bone Marrow
Adult
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Revels, Cheryl M
(715) 389-4177
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
DCP-001, Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Onitilo, Adedayo A
Treatment of Side Effects
Adult, Child
Implement a screening tool in NCORP to collect broader demographic and clinical data to generate hypothesis and research questions in the following areas of research: cancer screening, cancer prevention, symptom science, cancer care disparities, comparative effectiveness and cancer care delivery research.
Baker, Jessica
(715) 344-3048
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)
Sharma, Rohit
Melanoma
Adult
Determine the association of GEP test result with SLNB surgical decisions in patients with SLNB-eligible T1-T2 melanoma Track and evaluate 5-year clinical outcomes for patients in each GEP subclass, including those who did and did not undergo SLNB and those with T3-T4 melanoma
Adam, Iddrisu
(715) 389-4041
Bulgrin, Angela M
(715) 221-7261
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
E4512, A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Onitilo, Adedayo A
Lung - Lung
Adult
This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Tumors with this mutation may respond to treatments that target the mutation, such as crizotinib. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. It is not yet known if crizotinib may be an effective treatment for treating non-small cell lung cancer with an ALK fusion mutation.
Adam, Iddrisu
(715) 389-4041
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
EA1151, Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Onitilo, Adedayo A
Cancer Prevention - Breast
Adult
To compare the proportions of participants in the Tomosynthesis (TM) and Digital Mammography (DM) study arms experiencing the occurrence of an advanced breast cancer at any time during a period of 4.5 years from randomization,including the period of active screening and a period of clinical follow-up after the last screen (T4).
Bello, Tolulope O
(715) 221-7267
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
EA1181, (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Fagbemi, Seth O
Breast - Breast
Adult
To determine if 3-year recurrence-free survival (RFS) is greater than 92% among clinical stages II or IIIa patients with HER2-positive breast cancer who achieve pCR (ypT0/is ypN0) after preoperative therapy with 12 weeks of a taxane, trastuzumab (or FDA approved biosimilar) and pertuzumab (THP x 12). Post-operatively, patients will receive standard of care adjuvant locoregional therapy, plus completion of 12 months of HER2-targeted therapy (and standard adjuvant endocrine therapy as appropriate).
Revels, Cheryl M
(715) 389-4177
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
EA2183, A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Tanawattanacharoen, P
Stomach, Intestine, Gut - Stomach, Esophagus
Stomach, Intestine, Gut - Gastric
Adult
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Wilson, Anna E
(715) 858-6860
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
EA2185, Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Tanimu, Sabo B
Stomach, Intestine, Gut - Pancreas
Cancer Supportive Care
Adult
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts.
Hurley, Alexa A
(715) 393-1019
Eau Claire Center
2116 Craig Rd
Eau Claire, WI  54701
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
EA3161, A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
Lee, David
Head/Neck
Adult
This phase II/III trials studies whether maintenance immunotherapy (nivolumab) following definitive treatment with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy such as cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether chemotherapy and radiation therapy followed by maintenance nivolumab therapy works better than chemotherapy and radiation therapy alone in treating patients with HPV positive oropharyngeal cancer.
Craig, Chani L
(715) 358-1838
Diagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI  54476
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476